{"id":"W2772341954","doi":"10.1093/annonc/mdx711.078","title":"KEYNOTE-629: Phase 2 trial of pembrolizumab in patients (pts) with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cetuximab; Response Evaluation Criteria in Solid Tumors; Tolerability; Internal medicine; Oncology; Clinical endpoint; Regimen; Phases of clinical research; Head and neck squamous-cell carcinoma; Clinical trial; Head and neck cancer; Cancer; Adverse effect; Immunotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008854188,0.001116231,0.001247417,0.0003062591,0.0003857829,0.0009292973,0.0007360227,0.001013464,0.01122213],"category_scores_gemma":[0.0006445036,0.0004493291,0.001205278,0.0002756802,0.0004527451,0.0009972146,0.0003593121,0.003046893,0.00194687],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006925298,"about_ca_system_score_gemma":0.0009913354,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001232486,"about_ca_topic_score_gemma":0.003895768,"domain_scores_codex":[0.9998026,0.00008033746,0.00001032275,0.0000405431,0.00001716012,0.00004894043],"domain_scores_gemma":[0.9997575,0.00003934486,0.00004332664,0.00001932386,0.00001823734,0.0001222083],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7927269,0.0204665,0.003454485,0.002199657,0.002144078,0.0002449205,0.0002409365,0.001912577,0.03149006,0.000608206,0.01437376,0.1301378],"study_design_scores_gemma":[0.8666825,0.1168539,0.006867251,0.00008490118,0.0008152275,0.00021244,0.00006798549,0.000703876,0.001930673,0.0002819751,0.005475236,0.00002391398],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9745774,0.005318972,0.0006808634,0.001705518,0.0005636474,0.003278114,0.004493866,0.0002768755,0.009104696],"genre_scores_gemma":[0.9692393,0.004379069,0.001882197,0.002602795,0.0003240774,0.002783719,0.005714689,0.00006379095,0.01301034],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01122213,"threshold_uncertainty_score":0.03754175,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09981705411407019,"score_gpt":0.4088673511182487,"score_spread":0.3090502970041785,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}